// App-Quantinova.ai

TPS2657 : SGNTGT-001: A phase 1 study of SEA‑TGT, an effector-function enhanced monoclonal antibody (mAb), in advanced malignancies (trial in progress).

Researchers

Presenter

  • Elena Garralda

Principal Investigators

  • Rachel E. Sanborn

  • Anna Rachel Minchom

  • Diwakar Davar

  • Giuseppe Curigliano

  • Vincent Ribrag

  • Amitkumar Mehta

  • Francine M. Foss

  • Jasmine M. Zain

  • Andres Forero-Torres

  • Stephen M. Ansell

Medical Centers

  • University Hospital Vall d'Hebron, Barcelona, Spain

  • Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, OR

  • Drug Development Unit, Royal Marsden Hospital and The Institute of Cancer Research, London, United Kingdom

  • UPMC Cancer Center, Pittsburgh, PA

  • European Institute of Oncology and University of Milan-Bicocca, Milan, Italy

  • Gustave-Roussy Institute, Villejuif Cedex, France

  • The University of Alabama Birmingham Comprehensive Cancer Center, Birmingham, AL

  • Yale New Haven Hospital, New Haven, CT

  • City of Hope, Duarte, CA

  • Seagen, Inc., Bothell, WA

  • Mayo Clinic, Rochester, MN

Locations

  • Spain

  • United States

  • United Kingdom

  • Italy

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Genetic Disorder

Disease

  • Squamous cell carcinoma of the head and neck

  • Diffuse large B-cell lymphoma

  • Triple-negative breast cancer

  • Hodgkin's Lymphoma

  • Peripheral T-cell lymphoma

  • Squamous cell carcinoma

  • B cell lymphomas

  • T-cell lymphoma

  • Bladder Cancer

  • Gynaecological cancer

  • Breast cancer

  • Solid malignancies

  • Lymphomas

  • Melanoma

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Pharmacodynamics

  • Open Label

  • Multicenteric

  • Expansion Study

  • Dose Escalation

Phase

  • I

Study Id's

  • NCT04254107

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved